Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
about
Eslicarbazepine acetate add-on for drug-resistant partial epilepsyA review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyUpdate on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsySafety and tolerability of perampanel: a review of clinical trial data.Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.Highights in the history of epilepsy: the last 200 yearsPharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepineEfficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Clinical utility of eslicarbazepine: current evidence.Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampusTime to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpointPerspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapyEvaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.New developments in the treatment of partial-onset epilepsy.Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Recent and future antiepileptic drugs and their impact on cognition: what can we expect?Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective.Pharmacotherapy for tonic-clonic seizures.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Drug-induced cerebellar ataxia: a systematic review.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.Eslicarbazepine acetate for the treatment of partial epilepsy.EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis.
P2860
Q24234598-7385EC49-5B80-41BE-BF28-D00413EA5B9AQ24621327-6FEA68DF-CFA4-416B-8C3F-D225ABB429B1Q26745780-0F100D36-E077-4572-80E3-39447512617BQ30597533-732EC402-0810-4146-BEB1-F4E6943A7E1BQ34086531-B7436FF2-D553-48A4-AF35-C5DB85335F29Q34151924-CAB3AF84-EEAD-48BD-966E-1FED6176AF37Q34276263-6F683EB5-45B9-4894-8761-E6E2EDBC7F41Q34329823-39FB2F63-93D3-44D6-BC82-13A705EF1A63Q34375311-E0052AD6-9860-4073-9234-87891521F9C8Q35087964-B25BADE0-AAFE-454D-9C37-0F46591D1897Q35531026-06ECC785-1A9F-40E4-83C4-177023DBA4C5Q35639962-D0469FC2-E45B-4FB4-B507-CBE5460C2B28Q35761335-71030306-BF76-44DE-B760-8B7B9BDE8B62Q35936036-72BB7520-D2AC-4ED7-BDFC-99B2D2CF0E80Q36284727-4B3F3B9F-1738-440F-B503-B0B2BE1488ADQ36337897-E6DD6D37-E2CB-4EF5-BEAC-255E347EA757Q37680030-F753AED7-45F0-4169-9B88-AF8156E53BA7Q37694387-2A7EA5DC-7214-476A-AEDB-33F2C0CE2416Q37754477-E8D7E0A4-F1BB-4C9A-BD09-166191D40653Q37831297-D732D6EA-2E97-4C0A-A2A2-9BCFFE8BA212Q37950518-F52939F7-D999-4D04-B91B-5774491BD255Q37957121-824927BF-7EBB-4094-9898-1EA940B4143CQ37964697-8E9FC3AE-3550-4451-BD26-2C25839EDAC5Q37968623-926A5830-EB40-4FDF-AF50-D955A70A7CBEQ37975526-7457922F-5C2F-47DA-AF31-3A9FFD950975Q37992162-985B7F09-8DE1-458C-B39F-AACCECE56219Q38014887-F517591A-50B9-437B-AF4C-618AB1BAAF1FQ38076077-3A33118A-910E-48BE-BD3B-EA3838D0BEC8Q38199973-78C60F64-B1E3-4C77-86AC-881ABA89C3F2Q38209529-FF9159A4-2CD1-468F-A884-9F4829426C3FQ38223958-4EE4F9FE-15B2-4674-A259-9DAF75EB3188Q38267726-0943146F-21D7-4F35-9094-BAABCD39BBF0Q38367761-A7F723D0-F1A5-4756-8CD1-034D08F07985Q38542064-02312551-ED3D-484B-A611-F953C024263EQ38656011-BDAE83A1-30FB-4155-B5BB-971924753E12Q38826584-A9997BA1-308A-4F26-A98A-0DC25E5F4766Q39116160-887F9E08-EBEE-488D-BBDD-79EAB1F40FBBQ39456360-7D86DE8C-741C-46F3-BBC9-5AB7535E51EDQ39520772-12F68577-E5E4-4B6E-82FF-80D919592E29Q42113049-8DE3A338-D951-44B6-9CBB-7F935253392A
P2860
Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@en
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@nl
type
label
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@en
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@nl
prefLabel
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@en
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@nl
P2093
P1476
Efficacy and safety of 800 and ...... actory partial-onset seizures.
@en
P2093
A Gil-Nagel
BIA-2093-303 Investigators Study Group
J Lopes-Lima
P304
P356
10.1111/J.1600-0404.2009.01218.X
P407
P577
2009-11-01T00:00:00Z